Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Soliton touts scar treatment study results

January 28, 2020 By Nancy Crotti

soliton-logoSoliton (NSDQ:SOLY) today announced positive results from treatment of fibrotic scars using its rapid acoustic pulse (RAP) device.

The proof-of-concept study, conducted 12 weeks after a single treatment with the device, showed that 10 patients’ keloid and hypertrophic scars were with smaller. Soliton licensed the technology from the University of Texas on behalf of the MD Anderson Cancer Center in Houston.

“We were excited to share the 12-week follow-up results at this key dermatology conference, amongst some of the top physicians in this field,” said Soliton president & CEO Dr. Christopher Capelli in a news release. “The clinical results clearly demonstrate that an overall average reduction in both the volume of the scars and the height of the scars at the 12-week follow-up after the intial single 6-minute treatment is continuing without the need for further dosing. We are very encouraged by these positive results that further substantiate the merit of our RAP device and look forward to continuing the development and enhancement of its clinical program.”

The data were presented at the Maui Derm for Dermatologists 2020 meeting. 3D scar assessment of the pre- and post-treatment photographs demonstrated an average reduction in volume of 29.6% (p<0.01) and an average reduction in height of 14.6% (p<0.005).

The scars were also smaller than they had been at six weeks, according to Soliton. Keloid scars are prone to recurrence after treatment with existing therapies. Patients treated with steroid injections see recurrence rates as high as 50%, while patients treated with a chemotherapeutic agent have recurrence rates as high as 47%, the company noted.

Soliton’s rapid acoustic pulse device won 510(k) clearance from the FDA in May 2019. The company raised $9.5 million in a private placement in June, led by a $5 million investment by its largest backer, Remeditex Ventures. It is also targeting the tattoo-removal market.

Grand View Research estimates the global market for keloid and hypertrophic scars may reach $10.2 billion by 2025.

Related Articles Read More >

Evonik invests in Revivo BioSystems and its compound-testing technology
Galien Foundation's Prix Galien USA awards 2021
The 18 most innovative medical devices of 2021
soliton-logo
Soliton signs Sanmina to produce its tattoo-removal device
Could this material predict bedsores?

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech